Post-earnings recap
Reported
Tue, Oct 30, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Insmed Inc's earnings report showed a significant loss per share, contributing to an 8.07% drop in stock price. The lack of revenue figures and guidance may have raised concerns among investors about the company's financial health and future prospects. The focus on clinical trials suggests that the company is prioritizing long-term growth over short-term results.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.14 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding future performance due to ongoing investments in research and development. They emphasized the importance of their clinical pipeline.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The company is focusing on its ongoing clinical trials and product development.